Effects of KRN633, an Inhibitor of Vascular Endothelial Growth Factor Receptor-2 Tyrosine Kinase, on Vascular Development of Placenta and Fetus of Mid Pregnancy in Mice

Inhibition of the vascular endothelial growth factor (VEGF) signaling pathway during pregnancy contributes to several pathologic pregnancies, such as hypertension, preeclampsia, and intrauterine growth restriction, but its effects on the fetus have not been fully examined. To determine how inhibitio...

Full description

Bibliographic Details
Main Authors: Yoshiko Wada, Hiromi Ozaki, Naomichi Abe, Tohru Nagamitsu, Hiroaki Ohta, Tsutomu Nakahara, Kunio Ishii
Format: Article
Language:English
Published: Elsevier 2010-01-01
Series:Journal of Pharmacological Sciences
Online Access:http://www.sciencedirect.com/science/article/pii/S1347861319309971
id doaj-2ec5e3ee391c42f5b17ad391009877ef
record_format Article
spelling doaj-2ec5e3ee391c42f5b17ad391009877ef2020-11-25T02:37:28ZengElsevierJournal of Pharmacological Sciences1347-86132010-01-011123290298Effects of KRN633, an Inhibitor of Vascular Endothelial Growth Factor Receptor-2 Tyrosine Kinase, on Vascular Development of Placenta and Fetus of Mid Pregnancy in MiceYoshiko Wada0Hiromi Ozaki1Naomichi Abe2Tohru Nagamitsu3Hiroaki Ohta4Tsutomu Nakahara5Kunio Ishii6Department of Molecular Pharmacology, Kitasato University School of Pharmaceutical Sciences, 5-9-1 Shirokane, Minato-ku, Tokyo 108-8641, Japan; Department of Obstetrics and Gynecology, Tokyo Women’s Medical University, Kawada-cho, 8-1 Shinjuku-ku, Tokyo 162-8666, JapanDepartment of Molecular Pharmacology, Kitasato University School of Pharmaceutical Sciences, 5-9-1 Shirokane, Minato-ku, Tokyo 108-8641, JapanDepartment of Molecular Pharmacology, Kitasato University School of Pharmaceutical Sciences, 5-9-1 Shirokane, Minato-ku, Tokyo 108-8641, JapanDepartment of Organic Synthesis, Kitasato University School of Pharmaceutical Sciences, 5-9-1 Shirokane, Minato-ku, Tokyo 108-8641, JapanDepartment of Obstetrics and Gynecology, Tokyo Women’s Medical University, Kawada-cho, 8-1 Shinjuku-ku, Tokyo 162-8666, JapanDepartment of Molecular Pharmacology, Kitasato University School of Pharmaceutical Sciences, 5-9-1 Shirokane, Minato-ku, Tokyo 108-8641, Japan; Corresponding author. nakaharat@pharm.kitasato-u.ac.jpDepartment of Molecular Pharmacology, Kitasato University School of Pharmaceutical Sciences, 5-9-1 Shirokane, Minato-ku, Tokyo 108-8641, JapanInhibition of the vascular endothelial growth factor (VEGF) signaling pathway during pregnancy contributes to several pathologic pregnancies, such as hypertension, preeclampsia, and intrauterine growth restriction, but its effects on the fetus have not been fully examined. To determine how inhibition of the VEGF signaling pathway affects the fetal vascular development of mid pregnancy, we treated pregnant mice daily with either the VEGF receptor-2 (VEGFR-2) tyrosine kinase inhibitor KRN633 (300 mg/kg, p.o.) or the vehicle from 13.5 to 15.5 day of pregnancy. On the 16.5 day of pregnancy, the vascular beds in the placenta and several organs of the fetus were visualized by fluorescent immunohistochemistry. All mice treated with KRN633 appeared healthy, and total numbers of fetuses per litter were unaffected. However, weights of the placenta and fetus from KRN633-treated mice were lower than those from the vehicle-treated ones. No external malformations and bleeding were observed in the placenta and fetus, whereas immunohistochemical analyses revealed that the vascular development in labyrinthine zone of placenta and fetal organs examined (skin, pancreas, kidney, and lung) were impaired by KRN633 treatment. These results suggest that inhibition of the VEGF signaling pathway during mid pregnancy suppresses vascular growth of both the placenta and fetus without obvious health impairments of mother mice and increases the risk of induction of intrauterine growth restriction. Keywords:: fetus, intrauterine growth restriction, placenta, vascular endothelial growth factor (VEGF), vascular developmenthttp://www.sciencedirect.com/science/article/pii/S1347861319309971
collection DOAJ
language English
format Article
sources DOAJ
author Yoshiko Wada
Hiromi Ozaki
Naomichi Abe
Tohru Nagamitsu
Hiroaki Ohta
Tsutomu Nakahara
Kunio Ishii
spellingShingle Yoshiko Wada
Hiromi Ozaki
Naomichi Abe
Tohru Nagamitsu
Hiroaki Ohta
Tsutomu Nakahara
Kunio Ishii
Effects of KRN633, an Inhibitor of Vascular Endothelial Growth Factor Receptor-2 Tyrosine Kinase, on Vascular Development of Placenta and Fetus of Mid Pregnancy in Mice
Journal of Pharmacological Sciences
author_facet Yoshiko Wada
Hiromi Ozaki
Naomichi Abe
Tohru Nagamitsu
Hiroaki Ohta
Tsutomu Nakahara
Kunio Ishii
author_sort Yoshiko Wada
title Effects of KRN633, an Inhibitor of Vascular Endothelial Growth Factor Receptor-2 Tyrosine Kinase, on Vascular Development of Placenta and Fetus of Mid Pregnancy in Mice
title_short Effects of KRN633, an Inhibitor of Vascular Endothelial Growth Factor Receptor-2 Tyrosine Kinase, on Vascular Development of Placenta and Fetus of Mid Pregnancy in Mice
title_full Effects of KRN633, an Inhibitor of Vascular Endothelial Growth Factor Receptor-2 Tyrosine Kinase, on Vascular Development of Placenta and Fetus of Mid Pregnancy in Mice
title_fullStr Effects of KRN633, an Inhibitor of Vascular Endothelial Growth Factor Receptor-2 Tyrosine Kinase, on Vascular Development of Placenta and Fetus of Mid Pregnancy in Mice
title_full_unstemmed Effects of KRN633, an Inhibitor of Vascular Endothelial Growth Factor Receptor-2 Tyrosine Kinase, on Vascular Development of Placenta and Fetus of Mid Pregnancy in Mice
title_sort effects of krn633, an inhibitor of vascular endothelial growth factor receptor-2 tyrosine kinase, on vascular development of placenta and fetus of mid pregnancy in mice
publisher Elsevier
series Journal of Pharmacological Sciences
issn 1347-8613
publishDate 2010-01-01
description Inhibition of the vascular endothelial growth factor (VEGF) signaling pathway during pregnancy contributes to several pathologic pregnancies, such as hypertension, preeclampsia, and intrauterine growth restriction, but its effects on the fetus have not been fully examined. To determine how inhibition of the VEGF signaling pathway affects the fetal vascular development of mid pregnancy, we treated pregnant mice daily with either the VEGF receptor-2 (VEGFR-2) tyrosine kinase inhibitor KRN633 (300 mg/kg, p.o.) or the vehicle from 13.5 to 15.5 day of pregnancy. On the 16.5 day of pregnancy, the vascular beds in the placenta and several organs of the fetus were visualized by fluorescent immunohistochemistry. All mice treated with KRN633 appeared healthy, and total numbers of fetuses per litter were unaffected. However, weights of the placenta and fetus from KRN633-treated mice were lower than those from the vehicle-treated ones. No external malformations and bleeding were observed in the placenta and fetus, whereas immunohistochemical analyses revealed that the vascular development in labyrinthine zone of placenta and fetal organs examined (skin, pancreas, kidney, and lung) were impaired by KRN633 treatment. These results suggest that inhibition of the VEGF signaling pathway during mid pregnancy suppresses vascular growth of both the placenta and fetus without obvious health impairments of mother mice and increases the risk of induction of intrauterine growth restriction. Keywords:: fetus, intrauterine growth restriction, placenta, vascular endothelial growth factor (VEGF), vascular development
url http://www.sciencedirect.com/science/article/pii/S1347861319309971
work_keys_str_mv AT yoshikowada effectsofkrn633aninhibitorofvascularendothelialgrowthfactorreceptor2tyrosinekinaseonvasculardevelopmentofplacentaandfetusofmidpregnancyinmice
AT hiromiozaki effectsofkrn633aninhibitorofvascularendothelialgrowthfactorreceptor2tyrosinekinaseonvasculardevelopmentofplacentaandfetusofmidpregnancyinmice
AT naomichiabe effectsofkrn633aninhibitorofvascularendothelialgrowthfactorreceptor2tyrosinekinaseonvasculardevelopmentofplacentaandfetusofmidpregnancyinmice
AT tohrunagamitsu effectsofkrn633aninhibitorofvascularendothelialgrowthfactorreceptor2tyrosinekinaseonvasculardevelopmentofplacentaandfetusofmidpregnancyinmice
AT hiroakiohta effectsofkrn633aninhibitorofvascularendothelialgrowthfactorreceptor2tyrosinekinaseonvasculardevelopmentofplacentaandfetusofmidpregnancyinmice
AT tsutomunakahara effectsofkrn633aninhibitorofvascularendothelialgrowthfactorreceptor2tyrosinekinaseonvasculardevelopmentofplacentaandfetusofmidpregnancyinmice
AT kunioishii effectsofkrn633aninhibitorofvascularendothelialgrowthfactorreceptor2tyrosinekinaseonvasculardevelopmentofplacentaandfetusofmidpregnancyinmice
_version_ 1724795474267865088